📊 AVIR Key Takeaways
Is Atea Pharmaceuticals, Inc. (AVIR) a Good Investment?
Atea demonstrates exceptional revenue growth of 622.5% YoY and maintains a fortress balance sheet with $79.3M cash and 7.89x current ratio, providing substantial financial resilience. However, the company faces critical profitability challenges with operating losses of -$48.0M and negative free cash flow of -$48.3M despite significant revenue scale, raising questions about operational efficiency and business model sustainability.
Atea Pharmaceuticals shows a sharp reported revenue increase, but the company remains deeply unprofitable with negative operating income, negative free cash flow, and weak returns on equity and assets. Its balance sheet is clean and liquidity is strong, but the current fundamentals suggest the revenue growth is not yet translating into durable operating leverage or self-funded business strength.
Atea Pharmaceuticals, Inc. Key Strengths (AVIR)
- Explosive revenue growth of 622.5% YoY indicates successful commercialization and strong market demand
- Fortress balance sheet: 7.89x current ratio, zero debt (0.00x D/E), $79.3M cash position provides ~1.7 years of operational runway
- Strong stockholders equity of $233.7M and total assets of $267.1M represent solid capital foundation
- Strong liquidity with a 7.82x current and quick ratio
- Debt-free balance sheet with 0.00x debt-to-equity
- Large equity base and meaningful cash reserves relative to liabilities
AVIR Stock Risks: Atea Pharmaceuticals, Inc. Investment Risks
- Significant operating losses (-$48.0M) and negative free cash flow (-$48.3M) despite high revenue, indicating unprofitable growth model
- Negative ROE (-19.4%) and ROA (-17.0%) show the company is destroying shareholder value and not generating returns on assets
- Cash burn rate of $46.4M annually will deplete capital reserves within 1.7 years without achieving profitability or raising additional capital
- Revenue growth quality appears weak because large reported revenue is accompanied by steep operating and net losses
- Cash burn remains significant with negative operating cash flow and free cash flow
- Profitability ratios are poor, including deeply negative margins, ROE, and ROA
Key Metrics to Watch
- Operating margin progression toward breakeven profitability
- Operating cash flow trend toward positive territory
- Free cash flow burn rate and cash runway depletion timeline
- Operating cash burn relative to cash balance
- Whether revenue converts into sustained improvement in operating margin and net losses
Atea Pharmaceuticals, Inc. (AVIR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.89x current ratio provides a solid financial cushion.
AVIR Profit Margin, ROE & Profitability Analysis
AVIR vs Healthcare Sector: How Atea Pharmaceuticals, Inc. Compares
How Atea Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Atea Pharmaceuticals, Inc. Stock Overvalued? AVIR Valuation Analysis 2026
Based on fundamental analysis, Atea Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Atea Pharmaceuticals, Inc. Balance Sheet: AVIR Debt, Cash & Liquidity
AVIR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Atea Pharmaceuticals, Inc.'s revenue has grown significantly by 622% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.00 indicates the company is currently unprofitable.
AVIR Revenue Growth, EPS Growth & YoY Performance
AVIR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | $32.8M | $1.5M | $0.05 |
| Q2 2022 | $60.4M | $1.5M | $0.02 |
| Q1 2022 | $66.0M | $30.7M | $0.34 |
| Q3 2021 | $32.8M | $1.5M | $0.05 |
| Q2 2021 | $60.4M | $1.5M | $0.02 |
| Q1 2021 | $66.0M | -$4.0M | $0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Atea Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
AVIR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Atea Pharmaceuticals, Inc. (CIK: 0001593899)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AVIR
What is the AI rating for AVIR?
Atea Pharmaceuticals, Inc. (AVIR) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVIR's key strengths?
Claude: Explosive revenue growth of 622.5% YoY indicates successful commercialization and strong market demand. Fortress balance sheet: 7.89x current ratio, zero debt (0.00x D/E), $79.3M cash position provides ~1.7 years of operational runway. ChatGPT: Strong liquidity with a 7.82x current and quick ratio. Debt-free balance sheet with 0.00x debt-to-equity.
What are the risks of investing in AVIR?
Claude: Significant operating losses (-$48.0M) and negative free cash flow (-$48.3M) despite high revenue, indicating unprofitable growth model. Negative ROE (-19.4%) and ROA (-17.0%) show the company is destroying shareholder value and not generating returns on assets. ChatGPT: Revenue growth quality appears weak because large reported revenue is accompanied by steep operating and net losses. Cash burn remains significant with negative operating cash flow and free cash flow.
What is AVIR's revenue and growth?
Atea Pharmaceuticals, Inc. reported revenue of $351.4M.
Does AVIR pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AVIR SEC filings?
Official SEC filings for Atea Pharmaceuticals, Inc. (CIK: 0001593899) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVIR's EPS?
Atea Pharmaceuticals, Inc. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AVIR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Atea Pharmaceuticals, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AVIR stock overvalued or undervalued?
Valuation metrics for AVIR: ROE of -19.4% (sector avg: 15%), net margin of -12.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AVIR's AI grade for 2026?
Our dual AI analysis gives Atea Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AVIR's free cash flow?
Atea Pharmaceuticals, Inc.'s operating cash flow is $-46.4M, with capital expenditures of $1.9M. FCF margin is -13.8%.
How does AVIR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -12.9% (avg: 12%), ROE -19.4% (avg: 15%), current ratio 7.89 (avg: 2).